Select a country
Imraldi™ (adalimumab) is indicated for a wide range of immune-mediated inflammatory diseases (rheumatological, dermatological, gastroenterological and opthalmological diseases).
Key safety information to help with Imraldi™ (adalimumab) use in clinical practice.
a The syringe or pen must be protected from light, and discarded if not used within the 28-day period.
b The 28 days out of the fridge stability refers to Imraldi™ standard formulation.